Zeitview Acquires Heliolytics, Becoming the Market Leader in Solar Aerial Inspections
6.9.2023 13:00:00 EEST | Business Wire | Press release
Zeitview today takes the lead in advanced aerial inspections for energy and infrastructure by acquiring Heliolytics, which specializes in photovoltaic (PV) system performance via aerial inspection and integrated analytics. The acquisition of this former division of NovaSource Power Services enables the combining of Heliolytics' data insights with Zeitview’s expertise in aerial inspection technologies. The majority of Heliolytics staff will join Zeitview, and the team’s presence in Toronto, Canada, will continue. The amount of the deal was not disclosed.
"Heliolytics are pioneers in the solar industry and have earned a commendable reputation for their unwavering commitment to quality, precision, and exceptional customer service—values we hold in the highest esteem,” said Dan Burton, founder and Chief Executive Officer at Zeitview. “Their expertise and dedication are valuable as we continue developing groundbreaking solutions that redefine inspection standards within the renewable energy sector. We are excited for this next chapter in our journey, where our united teams create a complete market-winning solution."
For renewable energy customers, this collaboration reinforces Zeitview's multi-asset approach to solar, wind, and utilities. For property owners, it offers critical insights into the performance of their rooftop solar facilities. For all customers, Heliolytics' international operations in Europe, Latin America, and the Asian Pacific are also being combined with Zeitview's global footprint in those same regions.
“Joining forces with Zeitview is a tremendous opportunity to further the renewable energy industry,” said Jocelyne Moyer, Head of Heliolytics. Post-acquisition, Moyer takes the title of Senior Director of Strategy and Operations at Zeitview. “We have a shared commitment with Zeitview to deep client partnerships, science-driven innovation, and unparalleled responsiveness to our global clients. I am excited to join the leadership team and look forward to collaborations that will strengthen Zeitview’s role in the operations and maintenance of renewable energy assets.”
Heliolytics' inspection tools and integrated analytics are now supported by Zeitview's AI/ML data processing engine. With this addition, Zeitview doubles the reach and breadth of its airplane operations and adds topography, EPC, and drone solutions to Heliolytics, all of which can translate into faster, more comprehensive customer results.
With the sale of Heliolytics to Zeitview, NovaSource Power Services continues to offer best-in-class aerial inspection software and services to their customers via Zeitview.
“We are thrilled to continue our longstanding partnership with the Heliolytics team under the Zeitview name,” said Timo Moeller, Chief Growth Officer, NovaSource Power Services. “Zeitview’s impressive inspection and software tools will enhance the insights we currently use to support operations and maintenance requests. It is clear that the Zeitview team deeply understands our data needs and is committed to providing continued unrivaled expertise as aerial inspection providers to support our growth.”
A complete integration of Heliolytics operations, data capture, and software into Zeitview’s market-leading global solar solution is expected to be finished by the end of 2024.
To learn more about how Zeitview supports global energy and infrastructure through advanced inspections and actionable data, visit www.zeitview.com.
ABOUT ZEITVIEW
As a single partner for aerial inspections across a broad spectrum of industries, including solar, wind, real estate, telecom, and utility assets, Zeitview is trusted by the largest enterprises worldwide to deliver fast, accurate insights that optimize asset performance and reduce operating and maintenance costs. Combining state-of-the-art aerial inspection software with the ability to capture in-depth visual data via airplanes and drones, Zeitview harnesses the power of artificial intelligence and machine learning. Such aerial intelligence delivers customers actionable insights in near real-time and empowers organizations to make better-informed decisions about their most critical assets at scale.
Learn more about Zeitview's cutting-edge solutions at www.zeitview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906378784/en/
Contact information
Technica Communications for Zeitview
Cait Caviness
zeitview@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom